Immuno-oncology is one of the most promising and fastest growing areas of cancer research, as well as one of the most active areas in terms of licensing deals and acquisitions. PD-1/PD-L1 inhibitors are rapidly changing treatment paradigms in melanoma and non-small cell lung cancer, and they are also likely to gain further approvals for a wide variety of other cancers. Early clinical results for CAR-T cell therapies are promising, with response rates hovering around 90% for patients with multiply relapsed or refractory B-cell acute lymphoblastic leukemia. Expectations for other cancer vaccines have diminished after multiple failures.

This report is an overview of the field of immuno-oncology and the various classes of immuno-oncology therapies, both approved and in the pipeline. This report includes:

• Key Opinion Leader Interviews
• Coverage of key immuno-oncology targets and therapy approaches being investigated
• 10-year sales forecasts for selected key immuno-oncology drugs
• Immuno-oncology pipelines powered by BioMedTracker
• Development focus map

UPDATE (6/12/15): This report has been updated with new information from the latest ASCO meeting.

BioMedTracker is offering this report at a discount from list price to current subscribers. To purchase this report, please click on the purchase button linked at the top of this page. For a preview of the table of contents of this report, please click here.

This report is available for free to Datamonitor Healthcare subscribers. Please log into Datamonitor Healthcare and access the article through their website here.

For our disclosures, please read the BioMedTracker Research Standards.